Clinical Trials FDA Approval Generic Drugs Hormones 
XTalks
FEBRUARY 5, 2024
Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Nevertheless, Opdivo continues to hold strong and Bristol Myers Squibb filed an application with the FDA in December for Opdivo in combination with cisplatin chemotherapy as a first-line treatment in advanced urothelial carcinoma.
pharmaphorum
DECEMBER 1, 2021
Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023. Oral isotretinoin can also be effective but is associated with serious side effects so is generally a last-line option.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 5, 2024
Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Nevertheless, Opdivo continues to hold strong and Bristol Myers Squibb filed an application with the FDA in December for Opdivo in combination with cisplatin chemotherapy as a first-line treatment in advanced urothelial carcinoma.
XTalks
AUGUST 2, 2023
Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.
The Pharma Data
MAY 4, 2021
The findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. Lorbrena is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
Expert insights. Personalized for you.
101 
Let's personalize your content